Hepatocyte growth factor exerts beneficial effects on mice with type II diabetes‑induced chronic renal failure via the NF‑κB pathway

Cheng,Guiming; Tang,Xun; Zhang,Jun

doi:10.3892/mmr.2018.9297

Hepatocyte growth factor exerts beneficial effects on mice with type II diabetes‑induced chronic renal failure via the NF‑κB pathway

Authors:
- Guiming Cheng
- Xun Tang
- Jun Zhang
View Affiliations

Affiliations: Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, P.R. China
Published online on: July 19, 2018 https://doi.org/10.3892/mmr.2018.9297
Pages: 3389-3396

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Type II diabetes is associated with a low quality of life and inflammation, and is often accompanied by varying degrees of chronic renal failure. Chronic renal failure is considered one of the most important factors that aggravates diabetes and contributes to renal insufficiency in patients with diabetes though cellular fibrosis. It has previously been reported that hepatocyte growth factor (HGF) serves extensive biological roles, and is a multifunctional antifibrotic factor that is involved in kidney development, acute injury and regeneration. The present study aimed to investigate whether HGF exerts beneficial effects on type II diabetes‑induced chronic renal failure in a mouse model. Plasma concentration levels of HGF, tumor necrosis factor (TNF)‑α, monocyte chemoattractant protein (MCP)‑1, interleukin (IL)‑1 and IL‑6 were analyzed prior to and following treatment with HGF. Blood urea nitrogen, plasma creatinine concentrations, and electrolyte, total serum protein, parathyroid hormone and C‑reactive protein levels were analyzed by ELISA. The mechanism underlying the effects of the HGF‑mediated signaling pathway was also investigated in mice with type II diabetes‑induced chronic renal failure. Histological analysis was used to determine the therapeutic effects of HGF on mice with type II diabetes‑induced chronic renal failure. The results indicated that HGF exhibited lower plasma concentrations in mice with type II diabetes‑induced chronic renal failure compared with in healthy mice. In addition, treatment with HGF relieved chronic renal failure via inhibition of inflammation. The results indicated that TNF‑α, MCP‑1 and IL‑1 serum concentration levels were downregulated following treatment with HGF. Conversely, IL‑6 and vascular endothelial growth factor concentration was increased in the HGF‑treated mice compared with in the control mice. The results also demonstrated that HGF treatment downregulated the expression of nuclear factor (NF)‑κB molecules, and target molecules C‑C motif chemokine ligand (Ccl)2, Ccl5, intercellular adhesion molecule 1 and TNF‑α. The present study demonstrated that HGF markedly improved renal failure induced by type II diabetes in a mouse model; histological analyses revealed that renal cell injury was improved following treatment with HGF. In conclusion, these results suggested that HGF may exert beneficial effects on type II diabetes‑induced chronic renal failure via regulation of the NF‑κB signaling pathway.

View Figures

View References

1	Finlay E: Review: Most interventions for preventing bone disease in chronic renal failure improved biochemical outcomes. Arch Dis Child Educ Pract Ed. 97:402012. View Article : Google Scholar : PubMed/NCBI
2	Takase H, Nakazawa A, Yamashita S, Toriyama T, Sato K, Ueda R and Dohi Y: Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers. Metabolism. 56:559–564. 2007. View Article : Google Scholar : PubMed/NCBI
3	Varughese GI and Lip GY: Hypertension in patients with type-II diabetes: Relation to urinary albumin excretion, endothelial function and inflammation. J Hum Hypertens. 19:421–424. 2005. View Article : Google Scholar : PubMed/NCBI
4	Yamamoto S, Okada Y, Mori H, Nishida K, Uriu K and Tanaka Y: Type 2 diabetes mellitus complicated by hypertension in Japanese patients: Switching treatment from high-dose angiotensin II receptor blockers to losartan plus hydrochlorothiazide. Intern Med. 53:1283–1289. 2014. View Article : Google Scholar : PubMed/NCBI
5	Kalaitzidis R and Bakris G: Management of hypertension in patients with diabetes: The place of angiotensin-II receptor blockers. Diabetes Obes Metab. 11:757–769. 2009. View Article : Google Scholar : PubMed/NCBI
6	Hasvold LP, Bodegård J, Thuresson M, Stålhammar J, Hammar N, Sundström J, Russell D and Kjeldsen SE: Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: A study of 15,990 patients. J Hum Hypertens. 28:663–669. 2014. View Article : Google Scholar : PubMed/NCBI
7	Daimon M, Kamba A, Murakami H, Takahashi K, Otaka H, Makita K, Yanagimachi M, Terui K, Kageyama K, Nigawara T, et al: Association between pituitary-adrenal axis dominance over the renin-angiotensin-aldosterone system and hypertension. J Clin Endocrinol Metab. 101:889–897. 2016. View Article : Google Scholar : PubMed/NCBI
8	Ficek J, Malyszko J and Chudek J: Renalase and its role in the development of hypertension in patients with chronic renal failure. Przegl Lek. 72:306–308. 2015.(In Chinese). PubMed/NCBI
9	Kasacka I: Review article-involvement of gastric APUD cells in chronic renal failure. Acta Histochem. 105:319–327. 2003. View Article : Google Scholar : PubMed/NCBI
10	Bos-Touwen I, Schuurmans M, Monninkhof EM, Korpershoek Y, Spruit-Bentvelzen L, Ertugrul-van der Graaf I, de Wit N and Trappenburg J: Patient and disease characteristics associated with activation for self-management in patients with diabetes, chronic obstructive pulmonary disease, chronic heart failure and chronic renal disease: A cross-sectional survey study. PLoS One. 10:e01264002015. View Article : Google Scholar : PubMed/NCBI
11	Nair PA, Jivani NB and Diwan NG: Kyrle's disease in a patient of diabetes mellitus and chronic renal failure on dialysis. J Family Med Prim Care. 4:284–286. 2015. View Article : Google Scholar : PubMed/NCBI
12	Guntani A, Yamaoka T, Okadome J, Kawakubo E, Kyuragi R, Homma K, Iwasa K, Matsumoto T, Okazaki J and Maehara Y: Evaluation of the paramalleolar bypass for critical limb ischemia patients on hemodialysis with diabetes mellitus and chronic renal failure. Ann Vasc Dis. 6:596–600. 2013. View Article : Google Scholar : PubMed/NCBI
13	Guerra-Martin MD, Amador-Marin B and Martinez-Montil JM: Health problems of family caregivers of people over 65 suffering from chronic renal failure: A systematic review. An Sist Sanit Navar. 38:425–438. 2015.(In Chinese). PubMed/NCBI
14	Ramezani A, Nägga K, Hansson O, Lönn J, Sjöwall J, Katoozian F, Mansouri S and Nayeri F: Hepatocyte growth factor in cerebrospinal fluid differentiates community-acquired or nosocomial septic meningitis from other causes of pleocytosis. Fluids Barriers CNS. 12:222015. View Article : Google Scholar : PubMed/NCBI
15	Faletto DL, Kaplan DR, Halverson DO, Rosen EM and Vande Woude GF: Signal transduction in c-met mediated motogenesis. EXS. 65:107–130. 1993.PubMed/NCBI
16	Baum E, Pawlaczyk K, Maćkowiak B, Sosinska P, Matecka M, Kolodziejczak B, Musielak M and Breborowicz A: Levels of hepatocyte growth factor in serum correlate with quality of life in hemodialysis patients. Int J Clin Exp Pathol. 8:13477–13482. 2015.PubMed/NCBI
17	Mizuno S and Nakamura T: Molecular basis for HGF-mediated regression of renal fibrosis. Nihon Rinsho. 64 Suppl 2:S312–S321. 2006.(In Chinese).
18	Zhang SH, Wen KM, Wu W, Li WY and Zhao JN: Efficacy of HGF carried by ultrasound microbubble-cationic nano-liposomes complex for treating hepatic fibrosis in a bile duct ligation rat model, and its relationship with the diffusion-weighted MRI parameters. Clin Res Hepatol Gastroenterol. 37:602–607. 2013. View Article : Google Scholar : PubMed/NCBI
19	Hasmim M, Bruno S, Azzi S, Gallerne C, Michel JG, Chiabotto G, Lecoz V, Romei C, Spaggiari GM, Pezzolo A, et al: Isolation and characterization of renal cancer stem cells from patient-derived xenografts. Oncotarget. 7:15507–15524. 2016. View Article : Google Scholar : PubMed/NCBI
20	Friedewald WT, Levy RI and Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:499–502. 1972.PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Li M, Shi X, Chen F and Hao F: Daphnetin inhibits inflammation in the NZB/W F1 systemic lupus erythematosus murine model via inhibition of NF-κB activity. Exp Ther Med. 13:455–460. 2017. View Article : Google Scholar : PubMed/NCBI
23	Naganuma Y, Ichii O, Otsuka S, Hashimoto Y and Kon Y: Analysis of TdT-mediated dUTP nick end labeling (TUNEL)-positive cells associated with cardiac myogenesis in mouse embryo. J Vet Med Sci. 75:283–290. 2013. View Article : Google Scholar : PubMed/NCBI
24	Mallavia B, Recio C, Oguiza A, Ortiz-Muñoz G, Lazaro I, Lopez-Parra V, Lopez-Franco O, Schindler S, Depping R, Egido J and Gomez-Guerrero C: Peptide inhibitor of NF-κB translocation ameliorates experimental atherosclerosis. Am J Pathol. 182:1910–1921. 2013. View Article : Google Scholar : PubMed/NCBI
25	Akyüz A, Yıldız A, Akıl MA, Bilik MZ, İnci Ü, Kayan F, Yıldız İ, Yılmaz Z, Yıldırım Y and Ülgen MS: Assessment of right ventricular systolic function in patients with chronic renal failure before and after hemodialysis by means of various echocardiographic modalities. Turk Kardiyol Dern Ars. 42:717–725. 2014.(In Chinese). View Article : Google Scholar : PubMed/NCBI
26	Ma HB, Wang R, Yu KZ and Yu C: Dynamic changes of early-stage aortic lipid deposition in chronic renal failure rats and effects of decorin gene therapy. Exp Ther Med. 9:591–597. 2015. View Article : Google Scholar : PubMed/NCBI
27	Vahedi M, Malekzadeh H, Haybar H, Soltanian AR, Abdollahzadeh S, Yoosefi H, Seyedian M, Yazdanpanah L, Saeid A, Fooladi Shabanpour M and Ghasemi M: The relationship between salivary beta-2 microglobulin and uremia intensity in men with chronic renal failure. Cell J. 14:276–281. 2013.PubMed/NCBI
28	Silverberg D, Yalon T, Rimon U, Reinitz ER, Yakubovitch D, Schneiderman J and Halak M: Endovascular treatment of lower extremity ischemia in chronic renal failure patients on dialysis: Early and intermediate term results. Isr Med Assoc J. 15:734–738. 2013.PubMed/NCBI
29	Berry PA and Thomson SJ: Comment on O'Brien et al: Prevalence and outcome of cirrhosis patients admitted to UK intensive care: A comparison against dialysis-dependent chronic renal failure patients. Intensive Care Med. 38:1729author reply 1730. 2012. View Article : Google Scholar : PubMed/NCBI
30	Marcondes JA, Martins TC, Amaral AS and Nery M: Falsely elevated testosterone in a type 1 diabetes patients with acne and chronic renal failure on dialysis. Arq Bras Endocrinol Metabol. 56:319–323. 2012.(In Chinese). View Article : Google Scholar : PubMed/NCBI
31	Finegood DT: Obesity, inflammation and type II diabetes. Int J Obes Relat Metab Disord. 27 Suppl 3:S4–S5. 2003. View Article : Google Scholar : PubMed/NCBI
32	Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K and Hanefeld M: Subclinical inflammation in newly detected Type II diabetes and impaired glucose tolerance. Diabetologia. 45:1512002.PubMed/NCBI
33	Bitar MS, Ayed AK, Abdel-Halim SM, Isenovic ER and Al-Mulla F: Inflammation and apoptosis in aortic tissues of aged type II diabetes: Amelioration with alpha-lipoic acid through phosphatidylinositol 3-kinase/Akt- dependent mechanism. Life Sci. 86:844–853. 2010. View Article : Google Scholar : PubMed/NCBI
34	Mariappan N, Elks CM, Sriramula S, Guggilam A, Liu Z, Borkhsenious O and Francis J: NF-kappaB-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes. Cardiovasc Res. 85:473–483. 2010. View Article : Google Scholar : PubMed/NCBI
35	Shaarawy M, Fathy SA, Mehany NL and Hindy OW: Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure. Clin Chem Lab Med. 45:1498–1503. 2007. View Article : Google Scholar : PubMed/NCBI
36	Shalini B and Sharma JD: Beneficial effects of emblica officinalis on fluoride-induced toxicity on brain biochemical indexes and learning-memory in rats. Toxicol Int. 22:35–39. 2015. View Article : Google Scholar : PubMed/NCBI
37	Cizmeci D and Arkun Y: Regulatory networks and complex interactions between the insulin and angiotensin II signalling systems: Models and implications for hypertension and diabetes. PLoS One. 8:e836402013. View Article : Google Scholar : PubMed/NCBI